GlassScriptPhysician profile
Zubair Ahmed
NPI 1831386556
$36,418.80
in general payments reported to CMS, 2019-2025
41 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,825 · 2020: $935 · 2021: $1,241 · 2022: $4,258 · 2023: $6,081 · 2024: $4,408 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $17K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $16,521.94 |
| Food and Beverage | $10,638.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $12,966.42 | 2023-2025 | Naeotom Alpha, Artis Icono Floor |
| Abbott Laboratories | $5,820.05 | 2019-2025 | Triclip, Mitraclip, Esprit |
| Medtronic, INC. | $4,565.51 | 2021-2025 | Corevalve Evolut R, Aurora Ev-Icd Mri Surescan, In.Pact Admiral |
| Penumbra, INC. | $3,020.12 | 2022-2025 | Indigo System, Penumbra System |
| Medtronic Vascular, INC. | $2,260.04 | 2019-2020 | |
| Abiomed | $1,166.66 | 2021-2025 | Impella |
| Philips North America LLC | $820.37 | 2020-2023 | |
| Amgen INC. | $684.74 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $658.92 | 2019-2025 | |
| Edwards Lifesciences Corporation | $596.55 | 2020-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Inari Medical, INC. | $524.29 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novartis Pharmaceuticals Corporation | $524.15 | 2019-2025 | |
| Shockwave Medical, INC | $395.75 | 2022-2025 | |
| Cvrx, INC. | $385.68 | 2023-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $257.72 | 2019-2025 | Eliquis, Camzyos |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $215.84 | 2019-2024 | Xarelto |
| Biosense Webster, INC. | $191.60 | 2023-2025 | Carto 3 |
| Alnylam Pharmaceuticals INC. | $142.04 | 2022-2025 | Amvuttra |
| Bard Peripheral Vascular, INC. | $121.37 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $120.21 | 2019-2025 | Farxiga |
| Boston Scientific Corporation | $119.95 | 2019-2025 | General - Therapies |
| Livanova USA, INC. | $88.85 | 2022 | |
| Stryker Corporation | $87.24 | 2025 | Artix Mt, Clottriever Bold Catheter |
| Kiniksa Pharmaceuticals, LTD. | $83.87 | 2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.59 | 2019-2024 | Lifevest |
| Astellas Pharma US INC | $64.76 | 2019 | |
| Merck Sharp & Dohme LLC | $60.57 | 2022-2025 | Verquvo |
| Avinger INC. | $48.08 | 2021 | |
| Asahi Intecc USA, INC. | $47.61 | 2024-2025 | Asahi Peripheral Vascular Wires, Asahi Coronary Wires, Peripheral Vascular |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.74 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $46.32 | 2019 | |
| Lundbeck LLC | $40.52 | 2019 | |
| Amarin Pharma, INC. | $38.62 | 2019-2020 | |
| Esperion Therapeutics, INC. | $30.68 | 2020-2021 | |
| Novo Nordisk INC | $19.76 | 2023 | Ozempic, Rybelsus |
| Bridgebio Pharma, INC. | $15.39 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $13.93 | 2022 | |
| Portola Pharmaceuticals, LLC | $13.65 | 2019 | |
| Irhythm Technologies, INC. | $13.17 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Gilead Sciences, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zubair Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.